PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis
Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 w...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2017.1395805 |
| _version_ | 1797683761467359232 |
|---|---|
| author | Carlo Giovanni Carrera Paolo Dapavo Piergiorgio Malagoli Luigi Naldi Luisa Arancio Francesca Gaiani Colin Gerard Egan Marco Di Mercurio Angelo Cattaneo |
| author_facet | Carlo Giovanni Carrera Paolo Dapavo Piergiorgio Malagoli Luigi Naldi Luisa Arancio Francesca Gaiani Colin Gerard Egan Marco Di Mercurio Angelo Cattaneo |
| author_sort | Carlo Giovanni Carrera |
| collection | DOAJ |
| description | Background: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response. Results: Two hundred and fifty five patients were included. No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4%), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4%, p = .02). More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23%, p < .001) or ustekinumab (65.7 vs. 44.6%, p = .003). Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept. PASI100 response was achieved in ∼43% of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3%), increasing to 92.5, 85.4 and 35.7%, respectively by six months. PASI100 response was associated with psoriasis nail involvement or genital psoriasis. Conclusion: In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis. |
| first_indexed | 2024-03-12T00:19:32Z |
| format | Article |
| id | doaj.art-c1b3ca27fb24479f8fcb8ec4646b9ed3 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:19:32Z |
| publishDate | 2018-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-c1b3ca27fb24479f8fcb8ec4646b9ed32023-09-15T14:08:31ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532018-07-0129548148610.1080/09546634.2017.13958051395805PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasisCarlo Giovanni Carrera0Paolo Dapavo1Piergiorgio Malagoli2Luigi Naldi3Luisa Arancio4Francesca Gaiani5Colin Gerard Egan6Marco Di Mercurio7Angelo Cattaneo8Fondazione IRCCS Cà Granda – Ospedale Maggiore PoliclinicoUniversity of TurinAzienda Ospedaliera San Donato MilaneseOspedale San Bortolo – Azienda ULSS8Fondazione IRCCS Cà Granda – Ospedale Maggiore PoliclinicoAzienda Ospedaliera San Donato MilaneseCE Medical WritingHumanitas Research HospitalFondazione IRCCS Cà Granda – Ospedale Maggiore PoliclinicoBackground: Few studies have compared the use of different biologics in a real-life setting in plaque psoriasis patients. Objective: To compare the efficacy of biologics in psoriasis/psoriatic arthritis patients. Methods: Patients treated with adalimumab, etanercept and ustekinumab for at least 16 weeks were included. Achievement of Psoriasis Area Severity Index (PASI), PASI 90/100 response and time taken to achieve PASI 90/100 response were measured. Logistic regression was used to evaluate the effect of psoriasis localization on achievement of PASI 100 response. Results: Two hundred and fifty five patients were included. No difference was observed in PASI 90 response between etanercept and ustekinumab (65.5 vs. 55.4%), while adalimumab-treated patients had a higher response versusustekinumab (71.6 vs. 55.4%, p = .02). More patients achieved complete remission (PASI 100 response) with adalimumab versus etanercept (65.7 vs. 23%, p < .001) or ustekinumab (65.7 vs. 44.6%, p = .003). Adalimumab-treated patients achieving PASI 90 responded more quickly (by three and six months) versus ustekinumab or etanercept. PASI100 response was achieved in ∼43% of adalimumab and ustekinumab treated-patients by three months versus etanercept (14.3%), increasing to 92.5, 85.4 and 35.7%, respectively by six months. PASI100 response was associated with psoriasis nail involvement or genital psoriasis. Conclusion: In the real-life setting, adalimumab was the most effective biological agent for the treatment of plaque psoriasis.http://dx.doi.org/10.1080/09546634.2017.1395805psoriasispsoriatic arthritisbiological drugsadalimumabetanerceptustekinumab |
| spellingShingle | Carlo Giovanni Carrera Paolo Dapavo Piergiorgio Malagoli Luigi Naldi Luisa Arancio Francesca Gaiani Colin Gerard Egan Marco Di Mercurio Angelo Cattaneo PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis Journal of Dermatological Treatment psoriasis psoriatic arthritis biological drugs adalimumab etanercept ustekinumab |
| title | PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis |
| title_full | PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis |
| title_fullStr | PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis |
| title_full_unstemmed | PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis |
| title_short | PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis |
| title_sort | pace study real life psoriasis area and severity index pasi 100 response with biological agents in moderate severe psoriasis |
| topic | psoriasis psoriatic arthritis biological drugs adalimumab etanercept ustekinumab |
| url | http://dx.doi.org/10.1080/09546634.2017.1395805 |
| work_keys_str_mv | AT carlogiovannicarrera pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT paolodapavo pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT piergiorgiomalagoli pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT luiginaldi pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT luisaarancio pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT francescagaiani pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT colingerardegan pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT marcodimercurio pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis AT angelocattaneo pacestudyreallifepsoriasisareaandseverityindexpasi100responsewithbiologicalagentsinmoderateseverepsoriasis |